MARKET

JAZZ

JAZZ

Jazz Phrmt
NASDAQ

Real-time Quotes | Nasdaq Last Sale

128.64
-4.58
-3.44%
Closed 17:59 09/20 EDT
OPEN
131.00
PREV CLOSE
133.22
HIGH
132.43
LOW
128.26
VOLUME
933.22K
TURNOVER
--
52 WEEK HIGH
189.00
52 WEEK LOW
127.83
MARKET CAP
7.89B
P/E (TTM)
136.24
1D
5D
1M
3M
1Y
5Y
Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12
Zacks.com · 3d ago
Jazz Pharmaceuticals Announces Xywav Investor Webcast On Oct. 13, 2021
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will host a webcast on Wednesday, October 13, 2021 at 4:30 p.m. ET / 9:30 p.m. IST to provide an update on
Benzinga · 09/13 20:16
Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Wednesday, October 13, 2021 at 4:30 p.m. ET / 9:30 p.m. IST to provide an update on Xywav® (calcium, magnesium, potassium and sodium oxybates), the first and on...
PR Newswire · 09/13 20:15
Are CBD Stocks Ready to Ride Again? (JAZZ, YCBD, NEPT, CVSI, MJNA, ALST)
WallStreetPR · 09/09 11:07
Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming virtual investor conferences:
PR Newswire - PRF · 09/08 20:15
Sales Of Three Major Pharmaceutical Cannabis Products Set To Reach €1.8 Billion By 2025
By Prohibition Partners Combined sales of the three most lucrative cannabis pharmaceuticals products - Epidiolex®, Dronabinol and Sativex® - are set to reach €1.8 billion by 2025, according to a new report. 
Benzinga · 09/08 15:57
Jazz (JAZZ) Down 14.1% Since Last Earnings Report: Can It Rebound?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/02 15:31
Clinigen Group Says Elmar Schnee to Become Chairman With Immediate Effect
marketwatch.com · 09/01 07:02
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JAZZ. Analyze the recent business situations of Jazz Phrmt through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average JAZZ stock price target is 207.82 with a high estimate of 250.00 and a low estimate of 176.00.
EPS
Institutional Holdings
Institutions: 711
Institutional Holdings: 63.46M
% Owned: 103.42%
Shares Outstanding: 61.36M
TypeInstitutionsShares
Increased
196
5.87M
New
51
1.73M
Decreased
176
4.08M
Sold Out
141
1.98M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.35%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/Chief Executive Officer/Director
Bruce Cozadd
President
Daniel Swisher
Chief Financial Officer/Executive Vice President
Renee Gala
Chief Operating Officer/Executive Vice President/Managing Director
Christopher Tovey
Executive Vice President/General Manager
Kimberly Sablich
Executive Vice President
Robert Iannone
Senior Vice President
Finbar Larkin
Senior Vice President
Neena Patil
Senior Vice President
Samantha Pearce
Chief Accounting Officer/Vice President - Finance
Patricia Carr
Lead Director/Independent Director
Rick Winningham
Independent Director
Jennifer Cook
Independent Director
Patrick Enright
Independent Director
Peter Gray
Independent Director
Heather Mcsharry
Independent Director
Seamus Mulligan
Independent Director
Kenneth O'Keefe
Independent Director
Anne O'Riordan
Independent Director
Norbert Riedel
Independent Director
Mark Smith
Independent Director
Catherine Sohn
No Data
  • All
  • Financials
  • Insiders
More
About JAZZ
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.

Webull offers kinds of Jazz Pharmaceuticals PLC stock information, including NASDAQ:JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JAZZ stock methods without spending real money on the virtual paper trading platform.